Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Haruo Imawaka"'
Autor:
Ryuta Asaumi, Karsten Menzel, Wooin Lee, Ken‐ichi Nunoya, Haruo Imawaka, Hiroyuki Kusuhara, Yuichi Sugiyama
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 845-857 (2019)
As rifampicin can cause the induction and inhibition of multiple metabolizing enzymes and transporters, it has been challenging to accurately predict the complex drug–drug interactions (DDIs). We previously constructed a physiologically‐based pha
Externí odkaz:
https://doaj.org/article/6cea19c6dad64068b889793b645b8a6f
Autor:
Kenta Kono, Rui Fujimura, Yuka Nakamura, Kanoko Matsuura, Ken-ichi Nunoya, Yoshiyuki Yamaura, Haruo Imawaka, Hiroshi Watanabe, Toru Maruyama
Publikováno v:
Molecular Pharmaceutics. 19:798-804
In human plasma, the main agent of hydrolysis of the ester-type prodrug of levodopa, designated ONO-2160, is alpha-1-acid glycoprotein (AGP), which is a mixture of the F1*S and A variants at molar ratios of 3:1 to 2:1. In this study, the mechanism of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3924bd523d22919a13f657bf881071da
https://doi.org/10.1021/acs.molpharmaceut.1c00614
https://doi.org/10.1021/acs.molpharmaceut.1c00614
Publikováno v:
Xenobiotica. 50:526-535
1. Immunodeficient chimeric mice with humanised liver have been useful in predicting total clearance values of drugs in humans. However, their usefulness may currently be limited for specific compounds with interspecies differences.2. In vivo total c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a217aec44af5389af891b9b73d01362b
https://doi.org/10.1080/00498254.2019.1664791
https://doi.org/10.1080/00498254.2019.1664791
Autor:
Haruo Imawaka, Yuichi Sugiyama, Ryuta Asaumi, Hiroyuki Kusuhara, Ken-ichi Nunoya, Karsten Menzel, Wooin Lee
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 845-857 (2019)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
As rifampicin can cause the induction and inhibition of multiple metabolizing enzymes and transporters, it has been challenging to accurately predict the complex drug-drug interactions (DDIs). We previously constructed a physiologically-based pharmac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f1f1d77c151b300d0cb95f71fee9244
https://doi.org/10.1002/psp4.12457
https://doi.org/10.1002/psp4.12457
Autor:
Hoshimi Okawa, Kenta Kono, Haruo Imawaka, Toru Maruyama, Hiroshi Watanabe, Ken-ichi Nunoya, Yukina Fukuchi
Publikováno v:
Molecular Pharmaceutics. 16:4131-4138
ONO-2160 is a newly developed oral ester-type prodrug of levodopa for removing the problems in use of levodopa. It has a structure in which two of the same substituents are bound to levodopa. It is important to understand the pharmacokinetics and met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81554df3955232975a5e96db3cc0423
https://doi.org/10.1021/acs.molpharmaceut.9b00435
https://doi.org/10.1021/acs.molpharmaceut.9b00435
Autor:
Yoshiyuki Yamaura, Maeda Hitoshi, Jing Bi, Toru Takeo, Haruo Imawaka, Yuka Nakamura, Toru Maruyama, Hiroshi Watanabe, Ayumi Mukunoki, Ken-ichi Nunoya, Naomi Nakagata, Kenta Kono
Publikováno v:
Molecular Pharmaceutics. 19:3450-3450
Previously, we found that ONO-2160, an ester-type prodrug of levodopa (3-hydroxy-l-tyrosine), was mainly hydrolyzed in human plasma by α1-acid glycoprotein (AGP) with a partial contribution of albumin. In this study, we investigated whether ONO-2160
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9f72ef2c6233aa371439f0a1b04ef3a
https://doi.org/10.1021/acs.molpharmaceut.2c00598
https://doi.org/10.1021/acs.molpharmaceut.2c00598
Autor:
Haruo Imawaka, Ryuta Asaumi, Kenta Hashizume, Ken-ichi Nunoya, Kota Toshimoto, Yoshifusa Tobe, Wooin Lee, Yuichi Sugiyama
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 7:186-196
This study aimed to construct a physiologically based pharmacokinetic (PBPK) model of rifampicin that can accurately and quantitatively predict complex drug-drug interactions (DDIs) involving its saturable hepatic uptake and auto-induction. Using in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39397da43dcfb4754eec152317434082
https://doi.org/10.1002/psp4.12275
https://doi.org/10.1002/psp4.12275
Autor:
Ken-ichi Nunoya, Yoshifusa Tobe, Seiji Miyauchi, Takeshi Sawada, Ryuta Asaumi, Kota Toshimoto, Takanori Mori, Yuichi Sugiyam, Yoshitaka Hashimoto, Haruo Imawaka, Keisuke Kakimoto, Yukina Fukuchi, Takeyuki Iwata
Publikováno v:
Journal of Pharmaceutical Sciences. 106:2704-2714
The cause of nonlinear pharmacokinetics (PK) (more than dose-proportional increase in exposure) of a urea derivative under development (compound A: anionic compound [pKa: 4.4]; LogP: 6.5; and plasma protein binding: 99.95%) observed in a clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f920fe1db03e48db8fac1fb5ee78e11
https://doi.org/10.1016/j.xphs.2017.04.052
https://doi.org/10.1016/j.xphs.2017.04.052
Autor:
Shota Suzuki, Saki Izumi, Ken-ichi Nunoya, Takafumi Komori, Ryo Ito, Haruo Imawaka, Hidetaka Akita, Kenta Umehara, Keita Kitamura, Tomomi Furihata, Naomi Wakayama, Naohiko Anzai, Yoshiyuki Yamaura
Publikováno v:
Molecular pharmaceutics. 16(11)
Brain microvascular endothelial cells (BMEC), together with astrocytes and pericytes, form the blood-brain barrier (BBB) that strictly restricts drug penetration into the brain. Therefore, in central nervous system drug development, the establishment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ecef4ff81ffb2e041a63e0020beff5b
https://pubmed.ncbi.nlm.nih.gov/31573814
https://pubmed.ncbi.nlm.nih.gov/31573814
Publikováno v:
Drug Metabolism and Pharmacokinetics. 34:S69-S70
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba6e6365149e9761a735e264fcd3aacf
https://doi.org/10.1016/j.dmpk.2018.09.237
https://doi.org/10.1016/j.dmpk.2018.09.237